Citadel Advisors’s Audentes Therapeutics, Inc BOLD Stock Holding History

Citadel Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,900	Closed	-$233K	–	10601
2019 Q4	$233K	Buy	+3,900	New	+$146K	﹤0.01%	7971
2019 Q3	–	Sell	-5,900	Closed	-$223K	–	10098
2019 Q2	$223K	Sell	5,900 -5,900	-50%	-$227K	﹤0.01%	8034
2019 Q1	$460K	Sell	11,800 -900	-7%	-$25.8K	﹤0.01%	6933
2018 Q4	$271K	Buy	12,700 +3,000	+31%	+$77.4K	﹤0.01%	7436
2018 Q3	$384K	Buy	9,700 +1,200	+14%	+$44.7K	﹤0.01%	7152
2018 Q2	$325K	Buy	+8,500	New	+$315K	﹤0.01%	7081

Citadel Advisors's BOLD Position: Q4 2019 in Review

Citadel Advisors sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 1,017,783 shares — an estimated $38.2M sold.

Citadel Advisors first reported a position in BOLD in Q1 2017 and held it in 10 quarters. The position peaked at $28.6M in Q3 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

Citadel Advisors reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
Citadel Advisors sold 1,017,783 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $38.2M.
Citadel Advisors first reported a position in Audentes Therapeutics, Inc in Q1 2017 and held it in 10 quarters.
Citadel Advisors's Audentes Therapeutics, Inc position peaked at $28.6M in Q3 2019.
188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.